{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-ibd","title":"PT-141 for IBD (Crohn's / Colitis): Evidence Review","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\n\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\n\n## Why PT-141 might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\n\n## How these fit together\n\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\n\n## What the evidence actually shows\n\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141 itself receives no mention (source status: unsourced for direct link).\n\n## What scientists say\n\nResearchers describe melanocortin receptor activation as capable of down-regulating NF-κB and certain cytokines in inflamed gut tissue from animal work. They frame this as a possible future direction, not a current therapy. No statements link PT-141 specifically to IBD repair or suppression (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports of PT-141 use center on sexual function. No widespread IBD-specific threads appear in searched discussions. Isolated mentions treat it as unrelated to bowel inflammation (anecdotal tier: none found).\n\n## What people say on X\n\nPosts discuss PT-141 for arousal or libido. No posts connect it to Crohn's or colitis outcomes. Searches return zero relevant patient experiences (anecdotal tier: none found).\n\n## What we do not know\n\nWhether PT-141 crosses into gut repair pathways at meaningful levels in humans remains unknown. Long-term effects on intestinal inflammation lack any data. Interactions with standard IBD therapies stay unexamined. Human safety in active IBD patients is untested.\n\n## Safety and limits\n\nPT-141 carries documented side effects including nausea and flushing from its approved use in sexual dysfunction. Any extension to IBD would require separate safety evaluation. Current evidence supplies no basis for expecting benefit or ruling out harm in this context (speculative tier for IBD application).","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test PT-141 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct clinical data for the specific pairing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 2023 review examined melanocortin system effects in mouse colitis models but did not test PT-141.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s1"],"source_status":"sourced","why_material":"Separates general melanocortin findings from the peptide in question.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"PT-141 primary actions center on CNS melanocortin receptors for arousal rather than gut tissue repair.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Grounds the if-then logic in known receptor profile without claiming IBD benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10378568/","title":"The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials","quote":"This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.","summary":"2023 review of melanocortin system in IBD; mouse models only; no PT-141 data.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"4b10cbaacb4afae1bd1da37ff3dac24175f77c50ba0980a6fadcc75095102d98"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37508552/","title":"The Melanocortin System in Inflammatory Bowel Diseases","quote":"In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis.","summary":"Confirms preclinical focus on related melanocortin peptides, not PT-141.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"ok","quote_status":"verified","prev":"4b10cbaacb4afae1bd1da37ff3dac24175f77c50ba0980a6fadcc75095102d98","hash":"8cdf0972935b49f877e2823af29edd5c24c4501a428964636ded0b53548339e8"},{"id":"s3","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route)","quote":"Bremelanotide injection is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women who previously had no problems with sexual desire.","summary":"Official indication confirms CNS/arousal focus.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"http_403","quote_status":"unverified","prev":"8cdf0972935b49f877e2823af29edd5c24c4501a428964636ded0b53548339e8","hash":"f38dd572a4507d682a40693e5941d61c7fb4edd6bf67ce421bc87c8cebff1827"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:15:03.286Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for IBD (Crohn's / Colitis): Evidence Review","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\n\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\n\n## Why PT-141 might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\n\n## How these fit together\n\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\n\n## What the evidence actually shows\n\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141 itself receives no mention (source status: unsourced for direct link).\n\n## What scientists say\n\nResearchers describe melanocortin receptor activation as capable of down-regulating NF-κB and certain cytokines in inflamed gut tissue from animal work. They frame this as a possible future direction, not a current therapy. No statements link PT-141 specifically to IBD repair or suppression (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports of PT-141 use center on sexual function. No widespread IBD-specific threads appear in searched discussions. Isolated mentions treat it as unrelated to bowel inflammation (anecdotal tier: none found).\n\n## What people say on X\n\nPosts discuss PT-141 for arousal or libido. No posts connect it to Crohn's or colitis outcomes. Searches return zero relevant patient experiences (anecdotal tier: none found).\n\n## What we do not know\n\nWhether PT-141 crosses into gut repair pathways at meaningful levels in humans remains unknown. Long-term effects on intestinal inflammation lack any data. Interactions with standard IBD therapies stay unexamined. Human safety in active IBD patients is untested.\n\n## Safety and limits\n\nPT-141 carries documented side effects including nausea and flushing from its approved use in sexual dysfunction. Any extension to IBD would require separate safety evaluation. Current evidence supplies no basis for expecting benefit or ruling out harm in this context (speculative tier for IBD application).","claims":[{"id":"c1","text":"No human trials test PT-141 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct clinical data for the specific pairing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 2023 review examined melanocortin system effects in mouse colitis models but did not test PT-141.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Separates general melanocortin findings from the peptide in question.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"PT-141 primary actions center on CNS melanocortin receptors for arousal rather than gut tissue repair.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Grounds the if-then logic in known receptor profile without claiming IBD benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10378568/","title":"The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials","quote":"This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37508552/","title":"The Melanocortin System in Inflammatory Bowel Diseases","quote":"In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route)","quote":"Bremelanotide injection is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women who previously had no problems with sexual desire.","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":23154,"tokens_out":2239,"cost":0.03454,"prev_hash":"genesis","hash":"c13f8f9d9188c0f2c4973ec1de6ba0d723d61dfd4dd7f187462eb6c39b37c176"}],"provenance":[{"ts":"2026-06-30T01:15:03.286Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Ibd\nSlug: pt-141-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"pt-141\",\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn's / colitis)\",\"Why PT-141 might help you\",\"How these fit to","response":"{\"slug\":\"pt-141-ibd\",\"title\":\"PT-141 for IBD (Crohn's / Colitis): Evidence Review\",\"body\":\"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\\n\\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\\n\\n## Why PT-141 might help you\\n\\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\\n\\n## How these fit together\\n\\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\\n\\n## What the evidence actually shows\\n\\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141","tokens_in":23154,"tokens_out":2239,"cost":0,"prev":"genesis","hash":"9a072c08d00f2ee46d9e75a9f06bd1cfd02ffa4d6543c94e828da44590ff1fcc"},{"ts":"2026-07-17T02:41:06.983Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-ibd","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a072c08d00f2ee46d9e75a9f06bd1cfd02ffa4d6543c94e828da44590ff1fcc","hash":"a2b2a868067baf7eca439b3979d3fdeee34152508b772bd2e95965177f4accb4"}],"energy":{"passes":2,"tokens_in":23154,"tokens_out":2239,"tokens_total":25393,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a2b2a868067baf7eca439b3979d3fdeee34152508b772bd2e95965177f4accb4"},"posted_at":"2026-06-29T21:32:53.613Z","created_at":"2026-06-29T21:32:53.613Z","updated_at":"2026-07-17T02:41:06.983Z","machine":{"shape":"article.machine/v1","slug":"pt-141-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-ibd","json":"https://miscsubjects.com/api/articles/pt-141-ibd","bundle":"https://miscsubjects.com/api/articles/pt-141-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-ibd","json":"/api/articles/pt-141-ibd","markdown":"/api/articles/pt-141-ibd/bundle?format=markdown","skill":"/api/articles/pt-141-ibd/skill","topology":"/api/articles/pt-141-ibd/topology","versions":"/api/articles/pt-141-ibd/revisions","invocations":"/api/articles/pt-141-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"9a90d9b180057d813f8ed69e27fa8b16d2e5c447a6667a5f201dfecd85dd1235","object":{"object_type":"article-object","identity":{"id":"article:pt-141-ibd","slug":"pt-141-ibd","title":"PT-141 for IBD (Crohn's / Colitis): Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-ibd\ndescription: Apply the PT-141 for IBD (Crohn's / Colitis): Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 for IBD (Crohn's / Colitis): Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-ibd.\n- Read claims and relationships at /api/articles/pt-141-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have IBD Crohn's / colitis IBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle k\n\n## Representations\n\n- Human: /a/pt-141-ibd\n- JSON: /api/articles/pt-141-ibd\n- Relationships: /api/articles/pt-141-ibd/topology\n- History: /api/articles/pt-141-ibd/revisions\n"},"json":{"route":"/api/articles/pt-141-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-ibd/invocations?status=success","failure_events":"/api/articles/pt-141-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-ibd","title":"PT-141 for IBD (Crohn's / Colitis): Evidence Review","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\n\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\n\n## Why PT-141 might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\n\n## How these fit together\n\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\n\n## What the evidence actually shows\n\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141 itself receives no mention (source status: unsourced for direct link).\n\n## What scientists say\n\nResearchers describe melanocortin receptor activation as capable of down-regulating NF-κB and certain cytokines in inflamed gut tissue from animal work. They frame this as a possible future direction, not a current therapy. No statements link PT-141 specifically to IBD repair or suppression (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports of PT-141 use center on sexual function. No widespread IBD-specific threads appear in searched discussions. Isolated mentions treat it as unrelated to bowel inflammation (anecdotal tier: none found).\n\n## What people say on X\n\nPosts discuss PT-141 for arousal or libido. No posts connect it to Crohn's or colitis outcomes. Searches return zero relevant patient experiences (anecdotal tier: none found).\n\n## What we do not know\n\nWhether PT-141 crosses into gut repair pathways at meaningful levels in humans remains unknown. Long-term effects on intestinal inflammation lack any data. Interactions with standard IBD therapies stay unexamined. Human safety in active IBD patients is untested.\n\n## Safety and limits\n\nPT-141 carries documented side effects including nausea and flushing from its approved use in sexual dysfunction. Any extension to IBD would require separate safety evaluation. Current evidence supplies no basis for expecting benefit or ruling out harm in this context (speculative tier for IBD application).","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test PT-141 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct clinical data for the specific pairing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 2023 review examined melanocortin system effects in mouse colitis models but did not test PT-141.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2","s1"],"source_status":"sourced","why_material":"Separates general melanocortin findings from the peptide in question.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"PT-141 primary actions center on CNS melanocortin receptors for arousal rather than gut tissue repair.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Grounds the if-then logic in known receptor profile without claiming IBD benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10378568/","title":"The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials","quote":"This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.","summary":"2023 review of melanocortin system in IBD; mouse models only; no PT-141 data.","claim_ids":["c1","c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"4b10cbaacb4afae1bd1da37ff3dac24175f77c50ba0980a6fadcc75095102d98"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37508552/","title":"The Melanocortin System in Inflammatory Bowel Diseases","quote":"In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis.","summary":"Confirms preclinical focus on related melanocortin peptides, not PT-141.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"ok","quote_status":"verified","prev":"4b10cbaacb4afae1bd1da37ff3dac24175f77c50ba0980a6fadcc75095102d98","hash":"8cdf0972935b49f877e2823af29edd5c24c4501a428964636ded0b53548339e8"},{"id":"s3","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route)","quote":"Bremelanotide injection is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women who previously had no problems with sexual desire.","summary":"Official indication confirms CNS/arousal focus.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:15:02.303Z","link_status":"http_403","quote_status":"unverified","prev":"8cdf0972935b49f877e2823af29edd5c24c4501a428964636ded0b53548339e8","hash":"f38dd572a4507d682a40693e5941d61c7fb4edd6bf67ce421bc87c8cebff1827"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:15:03.286Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for IBD (Crohn's / Colitis): Evidence Review","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\n\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\n\n## Why PT-141 might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\n\n## How these fit together\n\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\n\n## What the evidence actually shows\n\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141 itself receives no mention (source status: unsourced for direct link).\n\n## What scientists say\n\nResearchers describe melanocortin receptor activation as capable of down-regulating NF-κB and certain cytokines in inflamed gut tissue from animal work. They frame this as a possible future direction, not a current therapy. No statements link PT-141 specifically to IBD repair or suppression (mechanistic tier).\n\n## What people say on Reddit\n\nAnecdotal reports of PT-141 use center on sexual function. No widespread IBD-specific threads appear in searched discussions. Isolated mentions treat it as unrelated to bowel inflammation (anecdotal tier: none found).\n\n## What people say on X\n\nPosts discuss PT-141 for arousal or libido. No posts connect it to Crohn's or colitis outcomes. Searches return zero relevant patient experiences (anecdotal tier: none found).\n\n## What we do not know\n\nWhether PT-141 crosses into gut repair pathways at meaningful levels in humans remains unknown. Long-term effects on intestinal inflammation lack any data. Interactions with standard IBD therapies stay unexamined. Human safety in active IBD patients is untested.\n\n## Safety and limits\n\nPT-141 carries documented side effects including nausea and flushing from its approved use in sexual dysfunction. Any extension to IBD would require separate safety evaluation. Current evidence supplies no basis for expecting benefit or ruling out harm in this context (speculative tier for IBD application).","claims":[{"id":"c1","text":"No human trials test PT-141 in IBD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes absence of direct clinical data for the specific pairing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 2023 review examined melanocortin system effects in mouse colitis models but did not test PT-141.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Separates general melanocortin findings from the peptide in question.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"PT-141 primary actions center on CNS melanocortin receptors for arousal rather than gut tissue repair.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Grounds the if-then logic in known receptor profile without claiming IBD benefit.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:15:02.874Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10378568/","title":"The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials","quote":"This review summarises the evidence acquired so far and highlights that molecules interfering with the melanocortin system could represent new drugs for treating IBD.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37508552/","title":"The Melanocortin System in Inflammatory Bowel Diseases","quote":"In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route)","quote":"Bremelanotide injection is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women who previously had no problems with sexual desire.","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":23154,"tokens_out":2239,"cost":0.03454,"prev_hash":"genesis","hash":"c13f8f9d9188c0f2c4973ec1de6ba0d723d61dfd4dd7f187462eb6c39b37c176"}],"provenance":[{"ts":"2026-06-30T01:15:03.286Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Ibd\nSlug: pt-141-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"pt-141\",\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn's / colitis)\",\"Why PT-141 might help you\",\"How these fit to","response":"{\"slug\":\"pt-141-ibd\",\"title\":\"PT-141 for IBD (Crohn's / Colitis): Evidence Review\",\"body\":\"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing gut lining damage. The intestinal barrier loses integrity. Immune cells release excess inflammatory signals. Tissue repair lags behind repeated injury. This cycle keeps symptoms active.\\n\\nLayers include epithelial breakdown, cytokine imbalance favoring inflammation, and disrupted mucosal healing. Mechanical or symptom-masking approaches may ease pressure short-term but do not address the core repair deficit.\\n\\n## Why PT-141 might help you\\n\\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\\n2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nPT-141 acts on melanocortin receptors in the central nervous system and periphery. If melanocortin pathways influence gut inflammation or repair signals in your case, the compound could intersect those routes. This remains a mechanistic link only. No direct mapping to IBD symptom relief exists in studied data.\\n\\n## How these fit together\\n\\nSingle-compound focus — PT-141 targets sexual / CNS arousal pathways. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct tissue repair or inflammation modulation. PT-141 stands alone here because its documented actions center on arousal circuits rather than primary gut repair.\\n\\n## What the evidence actually shows\\n\\nNo human trials test PT-141 in IBD patients (human tier: absent). No rat or mouse studies administer PT-141 in colitis models (preclinical tier: absent for this peptide). A 2023 review examined the broader melanocortin system in IBD using mouse colitis models and noted potential anti-inflammatory roles for related peptides such as α-MSH and KPV (preclinical tier: melanocortin system in general). PT-141","tokens_in":23154,"tokens_out":2239,"cost":0,"prev":"genesis","hash":"9a072c08d00f2ee46d9e75a9f06bd1cfd02ffa4d6543c94e828da44590ff1fcc"},{"ts":"2026-07-17T02:41:06.983Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-ibd","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a072c08d00f2ee46d9e75a9f06bd1cfd02ffa4d6543c94e828da44590ff1fcc","hash":"a2b2a868067baf7eca439b3979d3fdeee34152508b772bd2e95965177f4accb4"}],"energy":{"passes":2,"tokens_in":23154,"tokens_out":2239,"tokens_total":25393,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a2b2a868067baf7eca439b3979d3fdeee34152508b772bd2e95965177f4accb4"},"posted_at":"2026-06-29T21:32:53.613Z","created_at":"2026-06-29T21:32:53.613Z","updated_at":"2026-07-17T02:41:06.983Z","machine":{"shape":"article.machine/v1","slug":"pt-141-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-ibd","json":"https://miscsubjects.com/api/articles/pt-141-ibd","bundle":"https://miscsubjects.com/api/articles/pt-141-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-ibd","json":"/api/articles/pt-141-ibd","markdown":"/api/articles/pt-141-ibd/bundle?format=markdown","skill":"/api/articles/pt-141-ibd/skill","topology":"/api/articles/pt-141-ibd/topology","versions":"/api/articles/pt-141-ibd/revisions","invocations":"/api/articles/pt-141-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"9a90d9b180057d813f8ed69e27fa8b16d2e5c447a6667a5f201dfecd85dd1235"}}}